GlassScriptPhysician profile
Anne Compton Symbas
NPI 1003169509
$4,418.30
in general payments reported to CMS, 2019-2025
23 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $859 · 2022: $1,521 · 2023: $1,175 · 2024: $663 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,358.16 | 2021-2025 | |
| Allergan, INC. | $528.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $300.85 | 2021-2025 | |
| Janssen Biotech, INC. | $283.88 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $247.37 | 2021-2023 | |
| Lilly USA, LLC | $243.18 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $237.66 | 2021-2023 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $189.61 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $178.75 | 2021-2024 | Adbry |
| Pfizer INC. | $131.89 | 2021-2023 | |
| Galderma Laboratories, L.P. | $87.66 | 2021-2025 | Aklief, Nemluvio |
| Dermavant Sciences, INC. | $84.50 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $83.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Almirall LLC | $77.62 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.41 | 2022 | |
| Incyte Corporation | $46.44 | 2024-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $44.78 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $42.40 | 2021 | |
| Botanix Sb INC | $37.91 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $35.61 | 2024 | Zoryve |
| Paratek Pharmaceuticals, INC. | $24.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.08 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Symbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.